# Toyoaki Hida

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/toyoaki-hida/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,113 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 76 |
| i10-index | 209 |
| Last Known Institution | Saitama International Medical Center |
| OpenAlex ID | https://openalex.org/A5086229141 |
| ORCID iD | https://orcid.org/0000-0003-3537-0020 |
| Works | 449 |

## Researcher papers

- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study](https://scholariq.org/papers/ch5424802-ro5424802-for-patients-with-alk-rearranged-advanced-non-small-cell/)
- [Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)](https://scholariq.org/papers/clinical-efficacy-and-safety-of-nivolumab-results-of-a-u-m-u-ulticenter-op-u-e-u/)
- [Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer](https://scholariq.org/papers/randomized-phase-ii-study-of-first-line-carboplatin-paclitaxel-with-or-without/)
- [Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer](https://scholariq.org/papers/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-treatment/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Saitama International Medical Center](https://scholariq.org/institutions/saitama-international-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.